Matecki Stefan, Dridi Haikel, Jung Boris, Saint Nathalie, Reiken Steven R, Scheuermann Valérie, Mrozek Ségolène, Santulli Gaetano, Umanskaya Alisa, Petrof Basil J, Jaber Samir, Marks Andrew R, Lacampagne Alain
Inserm U1046, CNRS UMR 91214, Université de Montpellier, Centre Hospitalier Regional Universitaire de Montpellier, 34295 Montpellier, France;
Inserm U1046, CNRS UMR 91214, Université de Montpellier, Centre Hospitalier Regional Universitaire de Montpellier, 34295 Montpellier, France; Department of Anesthesiology and Critical Care Medicine, St. Eloi Teaching Hospital, 34295 Montpellier, France;
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9069-74. doi: 10.1073/pnas.1609707113. Epub 2016 Jul 25.
Ventilator-induced diaphragmatic dysfunction (VIDD) refers to the diaphragm muscle weakness that occurs following prolonged controlled mechanical ventilation (MV). The presence of VIDD impedes recovery from respiratory failure. However, the pathophysiological mechanisms accounting for VIDD are still not fully understood. Here, we show in human subjects and a mouse model of VIDD that MV is associated with rapid remodeling of the sarcoplasmic reticulum (SR) Ca(2+) release channel/ryanodine receptor (RyR1) in the diaphragm. The RyR1 macromolecular complex was oxidized, S-nitrosylated, Ser-2844 phosphorylated, and depleted of the stabilizing subunit calstabin1, following MV. These posttranslational modifications of RyR1 were mediated by both oxidative stress mediated by MV and stimulation of adrenergic signaling resulting from the anesthesia. We demonstrate in the murine model that such abnormal resting SR Ca(2+) leak resulted in reduced contractile function and muscle fiber atrophy for longer duration of MV. Treatment with β-adrenergic antagonists or with S107, a small molecule drug that stabilizes the RyR1-calstabin1 interaction, prevented VIDD. Diaphragmatic dysfunction is common in MV patients and is a major cause of failure to wean patients from ventilator support. This study provides the first evidence to our knowledge of RyR1 alterations as a proximal mechanism underlying VIDD (i.e., loss of function, muscle atrophy) and identifies RyR1 as a potential target for therapeutic intervention.
呼吸机诱导的膈肌功能障碍(VIDD)是指长时间控制性机械通气(MV)后出现的膈肌肌无力。VIDD的存在阻碍了呼吸衰竭的恢复。然而,导致VIDD的病理生理机制仍未完全明确。在此,我们在人类受试者和VIDD小鼠模型中发现,MV与膈肌肌浆网(SR)Ca(2+)释放通道/雷诺丁受体(RyR1)的快速重塑有关。MV后,RyR1大分子复合物发生氧化、S-亚硝基化、Ser-2844磷酸化,且稳定亚基钙稳蛋白1缺失。RyR1的这些翻译后修饰由MV介导的氧化应激和麻醉引起的肾上腺素能信号刺激共同介导。我们在小鼠模型中证明,这种异常的静息SR Ca(2+)泄漏导致MV持续时间较长时收缩功能降低和肌纤维萎缩。用β-肾上腺素能拮抗剂或S107(一种稳定RyR1-钙稳蛋白1相互作用的小分子药物)治疗可预防VIDD。膈肌功能障碍在MV患者中很常见,是患者无法撤机的主要原因。本研究首次为我们提供了证据,证明RyR1改变是VIDD(即功能丧失、肌肉萎缩)的近端机制,并将RyR1确定为治疗干预的潜在靶点。